Table 5.
Univariate |
Multivariable |
|||||
---|---|---|---|---|---|---|
OR | CI | p | OR | CI | p | |
Age | 1.02 | 1.00–1.04 | 0.12 | |||
Female | 1.18 | 0.58–2.39 | 0.65 | |||
Preoperative patient factors | ||||||
Compression | 1.82 | 0.83–4.03 | 0.14 | 2.57 | 0.93–7.05 | 0.07 |
Hypothyroidism or hyperthyroidisma | 5.32 | 1.78–15.9 | 0.003 | 6.46 | 1.61–26.0 | 0.009 |
Nodule size | 0.80 | 0.64–1.01 | 0.06 | |||
TI-RADS of NIFTP | ||||||
1 | Ref. | — | — | |||
2 | 0.48 | 0.05–4.41 | 0.52 | |||
3 | 0.84 | 0.40–1.92 | 0.74 | |||
4 | 0.82 | 0.41–1.62 | 0.38 | |||
5 | 1.80 | 0.79–4.12 | 0.16 | |||
TI-RADS of non-NIFTP nodule | ||||||
1 | Ref. | — | — | |||
2 | 5.20 | 0.57–47.7 | 0.15 | |||
3 | 2.43 | 0.56–10.6 | 0.24 | |||
4 | 0.51 | 0.18–1.49 | 0.22 | |||
5 | 0.53 | 0.13–2.16 | 0.38 | |||
FNA classification of dominant nodule | ||||||
Indeterminate | Ref. | — | — | |||
Benign | 0.48 | 0.15–1.51 | 0.21 | |||
AUS/FLUS | 0.72 | 0.37–1.38 | 0.32 | |||
FN/SFN | 0.67 | 0.28–1.62 | 0.38 | 0.21 | 0.05–0.83 | 0.03 |
Suspicious for malignancy | 2.97 | 1.10–8.03 | 0.03 | 3.39 | 1.15–10.0 | 0.03 |
Malignant | 8.90 | 0.97–81.7 | 0.05 | 9.12 | 0.88–94.3 | 0.06 |
Underwent FNA of non-NIFTP nodule | 3.66 | 1.59–8.42 | 0.002 | 6.66 | 2.07–21.4 | 0.001 |
Suspicious molecular testing | 0.80 | 0.43–1.51 | 0.50 |
Bold: statistically significant.
Patients are clinically diagnosed with hypothyroidism or hyperthyroidism with abnormal TSH levels, or either on thyroid replacement medication or thyroid suppressive therapy.
CI, confidence interval; OR, odds ratio; Ref.: Reference variable for multivariable analysis.